I’ll now turn to the meat of my comments regarding our sources of growth in light of the changes from the DSM transaction. Fundamentally, our future success relies on execution and not new technology development. It therefore follows that there’s a lot of transparency into our growth going forward. Today, we sell eight products under three product lines, and simply put, our growth is coming from these eight products and our product pipeline.We anticipate providing more detail at our capital markets day this summer, but given the focus over the last few weeks from investors on our current growth profile, I’d like to be clear about our pipeline as it stands today. In our animal health and nutrition product line, we are developing four enzymes together with Novus. Given that Verenium developed two of the four high-performing Phytase enzymes serving this large market today, we have a strong view of what’s required to succeed in animal feed, and we believe our offering will be highly attractive to this market.
Verenium Corporation's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.